Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 2/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 2/20 | 0.32 |
| ▸ | DGKA | P23743 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4737714 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL9310640 | 0.93 | SPHK2 (0.44) | CES1CES2ALDH1A1SPHK2SPHK1 | |
| SCHEMBL11206862 | 0.88 | SPHK2 (0.50) | CES1CES2ALDH1A1SPHK2SPHK1 | |
| Hydrochloric Acid SCHEMBL2418042 | 0.87 | GAA (0.38) | ALDH1A1SPHK2SPHK1FAAHDGKA | |
| Hydrochloric Acid SCHEMBL2419949 | 0.87 | GAA (0.38) | ALDH1A1SPHK2SPHK1FAAHDGKA | |
| Hydrochloric Acid SCHEMBL2420200 | 0.87 | GAA (0.38) | ALDH1A1SPHK2SPHK1FAAHDGKA | |
| SCHEMBL8346390 | 0.87 | ALDH1A1 (0.36) | ALDH1A1SPHK2SPHK1FAAHDGKA | |
| Hydrochloric Acid SCHEMBL1965409 | 0.84 | — | — | |
| SCHEMBL989725 | 0.84 | GAA (0.39) | CES1CES2ALDH1A1SPHK2SPHK1 | |
| SCHEMBL988320 | 0.84 | GAA (0.39) | CES1CES2ALDH1A1SPHK2SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12168655-B2 | Apelin receptor agonists and methods of use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-12-17 | — | — | US | disclosed |
| CN-116332873-A | Protein tyrosine phosphatase inhibitors and methods of use thereof | 卡里科生命科学有限责任公司 | 2023-06-27 | — | — | CN | disclosed |
| US-20220315569-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE | BRISTOL MYERS SQUIBB CO (US) | 2022-10-06 | — | — | US | disclosed |
| US-11390616-B2 | Apelin receptor agonists and methods of use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3938038-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | Calico Life Sciences LLC (US) | 2022-01-19 | — | — | EP | disclosed |
| EP-3433247-B1 | 6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDINE-5-CARBOXAMIDES AS APJ AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-09-08 | — | — | EP | disclosed |
| US-20210198246-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE | BRISTOL MYERS SQUIBB CO (US) | 2021-07-01 | — | — | US | disclosed |
| EP-3468956-B1 | 6-HYDROXY-5-(PHENYL/HETEROARYLSULFONYL)PYRIMIDIN-4(1H)-ONES AS APJ AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-03-03 | — | — | EP | disclosed |
| EP-3383860-B1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE | BRISTOL MYERS SQUIBB CO (US) | 2021-01-20 | — | — | EP | disclosed |
| EP-3390400-B1 | HETEROARYLHYDROXYPYRIMIDINONES AS AGONISTS OF THE APJ RECEPTOR | BRISTOL MYERS SQUIBB CO (US) | 2021-01-20 | — | — | EP | disclosed |
| US-5153197-A | Treatment of hypertension with angiotensin II blocking imidazoles | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-10-06 | — | — | US | disclosed |
| US-5138069-A | Treating hypertension and congestive heart failure | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-08-11 | — | — | US | disclosed |
| US-5128355-A | Hypotensive | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-07-07 | — | — | US | disclosed |
| EP-0483683-A2 | Thienoimidazole derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1992-05-06 | — | — | EP | disclosed |
| EP-0434038-A1 | Fused imidazole derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1991-06-26 | — | — | EP | disclosed |
| EP-0425921-A1 | Benzimidazole derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1991-05-08 | — | — | EP | disclosed |
| EP-0407102-A1 | Substituted imidazo-fused 5-membered ring heterocycles as angiotensin II antagonists | MERCK & CO. INC. (US) | 1991-01-09 | — | — | EP | disclosed |
| EP-0324377-A2 | Angiotensin II receptor blocking imidazoles and combinations thereof with diuretics and NSaids | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-07-19 | — | — | EP | disclosed |
| EP-0253310-A2 | Angiotensin II receptor blocking imidazoles | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-01-20 | — | — | EP | disclosed |
| EP-0046349-A1 | Clavulanic acid derivatives, their preparation and use | BEECHAM GROUP PLC (GB) | 1982-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11390616-B2 | Apelin receptor agonists and methods of use | APLNR, AP2B1, AP3B1 | CES1 3998/4885CES2 4218/4885ALDH1A1 1981/4885 |
| US-20210198246-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE | APLNR, AP2B1, AP3B1 | CES1 3998/4885CES2 4218/4885ALDH1A1 1981/4885 |
| US-12168655-B2 | Apelin receptor agonists and methods of use | APLNR, AP2B1, AP3B1 | CES1 3998/4885CES2 4218/4885ALDH1A1 1981/4885 |
| US-20220315569-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE | APLNR, AP2B1, AP3B1 | CES1 3998/4885CES2 4218/4885ALDH1A1 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.